Adaptimmune Therapeutics PLC — Director's Dealing 2024

Mar 26, 2024

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2024-03-08

Reporting Person: EcoR1 Capital, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	164424420	Indirect

Footnotes

F1: These Ordinary Shares are held through 27,404,070 American Depository Shares, each representing 6 Ordinary Shares.

F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and the other reporting person. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 3d-5(b) under the Securities and Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

F3: Qualified Fund beneficially owns 155,106,660 Ordinary Shares.